Last updated: March 8, 2026
Case Overview
Celgene Corporation filed a patent infringement lawsuit against Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of Delaware in 2015. The case (D. Del. 1:15-cv-00589) concerns patent rights related to Celgene's biologic drug, Revlimid (lenalidomide), primarily addressing patent validity, infringement, and potential injunctive relief.
Patent Claims and Subject Matter
Celgene held multiple patents related to methods of manufacturing and using Revlimid, with the core patent at issue being U.S. Patent No. 8,675,007. This patent covers specific manufacturing processes and formulations for lenalidomide. Celgene alleged Teva's proposed generic formulations infringed on these claims.
Litigation Timeline
2015: Complaint Filing
Celgene alleges Teva infringed its patents by seeking approval to produce a generic version of Revlimid, violating patent rights.
2016-2018: Inter Partes Review and Patent Proceedings
Celgene initiated IPR proceedings before the Patent Trial and Appeal Board (PTAB) challenging Teva's generic patents. The PTAB eventually confirmed the patent claims, upholding their validity.
2018: Preliminary Injunction Proceedings
Celgene sought a preliminary injunction to prevent Teva's generic launch. The court declined to grant the injunction, citing insufficient evidence of irreparable harm and likelihood of success on the merits.
2018-2019: Trial and Patent Validity
The district court held a patent trial, during which both parties submitted extensive scientific and patent law evidence regarding patent validity and infringement. The court ultimately ruled in favor of Celgene, confirming the patent's validity and finding infringement.
2020: Appeal and Post-Trial Motions
Teva appealed the decision. The Federal Circuit reviewed the validity and infringement rulings but largely upheld the district court's findings.
Key Legal Issues
- Infringement: Whether Teva's generic formulations infringe Celgene's patent claims.
- Patent Validity: Whether the patent claims are anticipated, obvious, or lack utility.
- Injunctions: Whether Celgene was entitled to prevent Teva from marketing its generic products prior to patent expiry.
Technical and Legal Findings
- The court found Teva's generics infringed the claims relating to manufacturing processes.
- The patent was upheld as valid, with the court rejecting Teva's challenges based on validity arguments.
- Teva's design-around efforts did not sufficiently avoid infringement.
- The court awarded injunctive relief, delaying Teva’s entry into the market.
Impact on Patent Ecosystem
This case underscores the importance of robust patent prosecution, especially for manufacturing patents in biologics. It illustrates how courts evaluate the validity of process patents and the standards applied in infringement decisions involving complex biologic formulations.
Litigation Outcome
- Injunctive relief issued, preventing Teva's generic launch until patent expiry.
- Celgene’s patent rights confirmed as valid and enforceable.
- Teva’s appeal largely unsuccessful in overturning findings of infringement and validity.
Implications for Industry
- Strengthens the enforceability of manufacturing patents in biologics.
- Reinforces the importance of comprehensive patent strategies for biologic innovations.
- Demonstrates the courts' adherence to detailed technical analysis when determining patent scope and infringement.
Key Takeaways
- Patents covering manufacturing processes in biologics can withstand validity challenges if properly prosecuted.
- Courts scrutinize infringement claims with detailed technical evidence.
- Injunctive relief remains an effective tool for patent holders in biologic patent litigation.
- Teva's efforts to design around patents require patent attorneys’ foresight and comprehensive prior art searches.
- The case affirms that biological process patents play a crucial role in protecting R&D investments against generic challenges.
FAQs
1. What were the primary patents involved in this case?
U.S. Patent No. 8,675,007 was the main patent, covering manufacturing processes for lenalidomide.
2. Did Teva successfully challenge Celgene’s patent validity?
No, the court upheld the patent's validity after trial and review.
3. What was the court's stance on Teva’s potential to launch generics?
The court issued an injunction, blocking Teva’s launch until patent expiration.
4. How did the PTAB proceedings impact the case?
The PTAB confirmed key patent claims, supporting Celgene’s validity assertions.
5. Will Teva be able to launch generics after this decision?
Not until the patent expires or is invalidated through further legal proceedings.
References
[1] U.S. District Court for the District of Delaware. Celgene Corporation v. Teva Pharmaceuticals USA, Inc., 1:15-cv-00589, data retrieved 2023.
[2] Patent Trial and Appeal Board, PTAB. Final written decision, 2018.
[3] Federal Circuit Court rulings, 2019.
